Since 1996 some knowledgeable investors have said that a link-up between ABT abd BDX Biosciences would make sense. In addition, BDX has said publicly on many occasions up to late fiscal '00 that they are "committed to unlocking the value of its Bioscience business."
hd500, ABT would be a fine suitor, but some of use speculate that BD will "unlock the value of the Bioscience" business with a potential spinoff of the business, not necessarily a sale. Since 1996 BD Biosciences has acquired Pharmingen, Transduction Labs, Clontech, Biometric Imaging, and recently GenTest. The strategic direction seems to favor growing the business to add value and potentially unlock that value via separation from the huge mothership of syringes/vacutainers, et al. What do you think?